ArticleAmerican journal of cancer research2021

Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma.

Tong-Chao Zhao et al.PubMed ↗Full text ↗

No numbers read from the abstract.